Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Trillium Therapeutic (TRIL)

Trillium Therapeutic (TRIL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 684,135
  • Shares Outstanding, K 104,768
  • Annual Sales, $ 150 K
  • Annual Income, $ -59,350 K
  • 60-Month Beta 1.94
  • Price/Sales 4,813.67
  • Price/Cash Flow N/A
  • Price/Book 2.88
Trade TRIL with:

Options Overview

Details
  • Implied Volatility 102.64%
  • Historical Volatility 47.26%
  • IV Percentile 26%
  • IV Rank 33.57%
  • IV High 172.34% on 03/15/21
  • IV Low 67.42% on 06/01/21
  • Put/Call Vol Ratio 0.12
  • Today's Volume 166
  • Volume Avg (30-Day) 314
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 20,599
  • Open Int (30-Day) 20,879

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.16
  • Number of Estimates 2
  • High Estimate -0.11
  • Low Estimate -0.20
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.49 +5.08%
on 07/27/21
10.45 -34.74%
on 06/29/21
-3.16 (-31.66%)
since 06/28/21
3-Month
6.49 +5.08%
on 07/27/21
10.91 -37.49%
on 06/24/21
-1.70 (-19.95%)
since 04/28/21
52-Week
5.75 +18.61%
on 07/30/20
20.96 -67.46%
on 11/30/20
-0.44 (-6.06%)
since 07/28/20

Most Recent Stories

More News
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first acute myeloid...

TRIL : 6.82 (+4.44%)
TRIL.TO : 8.56 (+4.01%)
Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of Directors

Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment...

TRIL : 6.82 (+4.44%)
TRIL.TO : 8.56 (+4.01%)
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-621 in Combination With Doxorubicin in Leiomyosarcoma

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first patient...

TRIL : 6.82 (+4.44%)
TRIL.TO : 8.56 (+4.01%)
Trillium Therapeutics Joins Russell 2000(R) and 3000(R) Indices

Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, joins the broad-market...

TRIL : 6.82 (+4.44%)
TRIL.TO : 8.56 (+4.01%)
This Could Massively Disrupt the $24.35 Billion NSAID Market

As the standard first-line treatment for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, ...

TRIL : 6.82 (+4.44%)
EDSA : 5.00 (+1.63%)
ACRS : 15.34 (+4.07%)
BMY : 68.73 (+1.84%)
ATBPF : 2.7200 (-1.45%)
TRIL.TO : 8.56 (+4.01%)
ATE.TO : 3.42 (-1.44%)
Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the "Corporation"), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from...

TRIL : 6.82 (+4.44%)
TRIL.TO : 8.56 (+4.01%)
Novel Anti-Cancer Drugs Permeate the Marketplace

, /PRNewswire/ -- The cancer therapeutics market is one of the largest segments of the biotechnology industry. According to the National Cancer Institute, roughly 1.8 million people were diagnosed with...

SBFM : 0.1138 (+1.88%)
VSTM : 3.39 (+3.67%)
TRIL : 6.82 (+4.44%)
IMGN : 5.67 (+2.53%)
SRNE : 8.58 (+6.06%)
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment

PALM BEACH,  Fla., /PRNewswire/ -- Sadly, for patients, the pancreatic cancer market has been steadily rising over the past several years and will most likely continue to grow over the next couple of...

TRIL : 6.82 (+4.44%)
TRIL.TO : 8.56 (+4.01%)
ONCY : 2.40 (+2.56%)
ONC.TO : 3.00 (+1.69%)
ATNX : 3.88 (+5.15%)
SEEL : 2.38 (+3.48%)
MRKR : 2.19 (+4.29%)
Trillium Therapeutics Reports First Quarter 2021 Operating and Financial Results

Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the...

TRIL : 6.82 (+4.44%)
TRIL.TO : 8.56 (+4.01%)
Thinking about buying stock in GSX Techedu, Elys Game Technology, Navient Corp, Constellium SE, or Trillium Therapeutics?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GSX, ELYS, NAVI, CSTM, and TRIL.

ELYS : 4.31 (+8.56%)
NAVI : 19.87 (-3.12%)
TRIL : 6.82 (+4.44%)
CSTM : 19.03 (+5.72%)
GSX : 27.08 (-4.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin...

See More

Key Turning Points

3rd Resistance Point 7.44
2nd Resistance Point 7.20
1st Resistance Point 7.01
Last Price 6.82
1st Support Level 6.59
2nd Support Level 6.35
3rd Support Level 6.16

See More

52-Week High 20.96
Fibonacci 61.8% 15.15
Fibonacci 50% 13.35
Fibonacci 38.2% 11.56
Last Price 6.82
52-Week Low 5.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar